康灃生物科技（上海）股份有限公司 董事會薪酬委員會工作細則 第一章 總則 第二章 人員組成 1 第一條 為了進一步健全康灃生物科技（上海）股份有限公司（以下簡稱「公 司」或「本公司」）的薪酬管理制度，不斷完善激勵機制等薪酬體系， 完善公司治理結構，根據《中華人民共和國公司法》（以下簡稱「《公 司法》」）、《香港聯合交易所有限公司證券上市規則》（以下簡稱「《上 市規則》」）以及《公司章程》，公司特設立董事會（「董事會」）薪酬委 員會（「薪酬委員會」），並制定本工作細則（「工作細則」）。 第二條 薪酬委員會是董事會按照董事會決議設立的專門委員會，主要負責 研究公司董事、監事和高級管理人員的績效考核標準，進行考核並 提出建議；研究和審查公司董事、監事和高級管理人員的薪酬政策 和方案。 第三條 本細則所稱的董事是指在本公司領取薪酬的董事，高級管理人員是 指按照《公司章程》規定的由董事會聘任的總經理、副總經理、財務 負責人、董事會秘書以及董事會認定的其他高級管理人員。 第四條 本細則所稱薪酬是指董事會、監事會及高級管理人員從本公司獲取 的包括基本工資、考核工資、股權、期權及股份獎勵（如有）等形式 的各種報酬（「薪酬」） ...

第三章 職責職權 康灃生物科技（上海）股份有限公司 董事會審核委員會工作細則 第一章 總則 第二章 人員組成 1 第一條 為了進一步健全康灃生物科技（上海）股份有限公司（以下簡稱「公 司」或「本公司」）的決策功能，充分發揮審核委員會的監督作用，維 護審計工作獨立性，健全公司董事會（「董事會」）的審計、評價和監 督機制，確保公司董事會對公司的有效監督，完善公司治理結構， 根據《中華人民共和國公司法》（以下簡稱「《公司法》」）、《香港聯合 交易所有限公司證券上市規則》（以下簡稱「《上市規則》」）以及《公司 章程》，公司特設立董事會審核委員會（「審核委員會」），並制定本 工作細則（「工作細則」）。 第二條 審核委員會是董事會按照公司董事會決議設立的專門委員會，主要 負責公司內、外部審計的溝通、監督和核查工作，財務諮詢及其披 露的審閱，重大決策事項的監督和檢查工作，對董事會負責。 第三條 審核委員會由三名或以上非執行董事組成，其中獨立非執行董事佔 過半數。委員中至少應包含一名獨立非執行董事，且該名獨立非執 行董事應當具備《上市規則》第3.10(2)條所規定的適當專業資格， 或具備適當的會計或相關的財務管理專長。審核委 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 康灃生物科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 一份載有（其中包括）建議修訂詳情的通函及股東周年大會通知將根據上市規則適 時寄發予股東。 承董事會命 康灃生物科技（上海）股份有限公司 董事會主席 李克儉先生 香港，2025年3月31日 於本公告日期，董事會包括執行董事李克儉先生、朱軍先生及劉偉先生，非執行 董事呂世文先生及趙春生先生，以及獨立非執行董事高大勇博士、梁顯治先生、 覃正博士及胡赫男博士。 （股份代號：6922） 建議修訂公司章程 本公告乃由康灃生物科技（上海）股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則（「上市規則」）第13.51(1)條作出。 本公司董事（「董事」）會（「董事會」）宣佈，其已決議並建議修訂本公司現有公司 章程（「章程」），在慮及（其中包括）本公司運 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：6922） 董事會會議日期 康灃生物科技（上海）股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 董事（「董事」）會（「董事會」）茲宣佈謹定於2025年3月31日（星期一）召開董事會 會議，以（其中包括）審議及通過本集團截至2024年12月31日止年度之全年業績 及其發佈，以及審議派發末期股息之建議（如有）。 承董事會命 康灃生物科技（上海）股份有限公司 董事會主席 李克儉先生 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 康灃生物科技（上海）股份有限公司 於本公告日期，董事會包括執行董事李克儉先生、朱軍先生及劉偉先生，非執行 董事呂世文先生及趙春生先生，以及獨立非執行董事高大勇博士、梁顯治先生、 覃正博士及胡赫男博士。 香港，2025年3月19日 ...

康灃生物科技（上海）股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 本公司欣然宣布，於2025年3月6日，本集團的惡性狹窄冷凍消融系統（「惡性狹窄 冷凍消融系統」），本集團的呼吸介入產品之一，由冷凍治療設備及氣道冷凍消融 導管組成，已獲得國家藥品監督管理局（「國家藥監局」）授出的批文。 惡性狹窄冷凍消融系統為用於消融惡性氣道腫瘤組織、減少氣道再狹窄頻次的自 主研發冷凍消融系統。在手術過程中，惡性狹窄冷凍消融系統利用冷凍消融系統 產生的超低溫消融氣管腔內及腔壁的腫瘤細胞，然後通過復溫進一步破壞腫瘤細 胞。冷凍消融球囊能在較大範圍內對惡性腫瘤進行更徹底的消融，並推遲再狹窄 的時間。 本公司無法保證惡性狹窄冷凍消融系統的未來前景。本公司股東及潛在投資者於 買賣本公司證券時務請審慎行事。 承董事會命 康灃生物科技（上海）股份有限公司 董事會主席 李克儉先生 香港，202 ...

茲提述康灃生物科技（上海）股份有限公司（「本公司」）日期為2024年12月31日的 公告，內容有關重續現有總租賃協議（「該公告」）。除另有界定者外，本公告所用 詞彙與該公告所界定者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 康灃生物科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6922） 有關重續現有總租賃協議之持續關連交易的補充公告 董事會謹此向股東及本公司潛在投資者提供有關定價依據的進一步資料。誠如該 公告所披露，本集團於經續期總租賃協議項下訂立的租賃租金將由本公司與寧波 麟灃基於多項因素（包括但不限於鄰近地區類似物業的現行市場租金、租賃面積 及租賃期限）經公平磋商釐定。尤其是，本公司財務部將追蹤，並參考，位於將 出租之物業的鄰近地區且具有相近規格、用途、面積及性質的可資比較物業的現 行市場租金（包括位於麟灃醫療科技 ...

Cryofocus Medtech (Shanghai) Co., Ltd. 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 康灃生物科技（上海）股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6922） 持續關連交易 重續現有總租賃協議 背 景 茲提述本公司日期為2022年12月16日 內 容 有 關 現 有 總 租 賃 協 議 的 招 股 章 程。 根 據 現 有 總 租 賃 協 議，本 集 團 已 自 寧 波 麟 灃 租 賃 於 麟 灃 醫 療 科 技 產 業 園（位 於中國寧波市杭州灣新區濱海四路777號）的 物 業，用 作 工 廠 及 員 工 宿 舍 用 途，而 現 有 總 租 賃 協 議 將 於2024年12月31日 止 屆 滿。 董 事 會 謹 此 宣 佈，於2024年12月31日，本 公 司（為 及 代 表 其 本 ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 19,475,000, an increase of 3% from RMB 18,914,000 in the same period of 2023[6]. - Gross profit for the same period was RMB 15,281,000, up from RMB 14,638,000, reflecting a gross margin improvement[6]. - The company reported a net loss of RMB (55,953,000) for the first half of 2024, compared to a loss of RMB (47,428,000) in the prior year[6]. - Revenue increased from RMB 189 million for the six months ended June 30, 2023, to RMB 195 million for the six months ended June 30, 2024, representing a growth of 3.0%[34]. - Gross profit rose from RMB 146 million to RMB 153 million, with the gross margin improving from 77.4% to 78.5% due to higher sales of high-margin products[35]. - The company incurred a loss before tax of RMB 55,953 thousand, which is a decline from the loss of RMB 47,428 thousand reported in the previous year, reflecting an increase in losses of approximately 17.9%[79]. - The company reported a total of 125,013,402 non-listed shares and 114,096,598 H shares as of June 30, 2024[71]. - The basic and diluted loss per share for the period was RMB 0.22, compared to RMB 0.18 in the same period of 2023[79]. Research and Development - Research and development expenses increased to RMB (37,222,000) from RMB (34,330,000), indicating a focus on innovation despite losses[6]. - The company has established a product development team consisting of 90 internal R&D staff and 36 clinical operation team members as of June 30, 2024[31]. - The company holds 152 patents and has 53 patent applications in China and overseas as of June 30, 2024, to protect its technologies[31]. - Research and development expenses for the first half of 2024 were RMB 37,222 thousand, compared to RMB 34,330 thousand in the same period of 2023, showing an increase of approximately 8.5%[79]. Product Development and Approvals - The cardiac cryoablation system received production quality management standard approval in January 2024, marking a significant milestone[7]. - The company obtained market approval for the cryoadhesion treatment system in January 2024, following prior approvals for related equipment[7]. - The benign stricture cryoablation system entered confirmatory clinical trials in January 2024, indicating progress in product development[7]. - The Cryofocus cryoablation system is designed for hypertension treatment and is expected to receive regulatory approval by the second half of 2025[12]. - The chronic obstructive pulmonary disease cryo-spray treatment system entered confirmatory clinical trials in March 2023, with expected regulatory submission in the second half of 2025[14]. - The malignant stenosis cryoablation system's registration application was submitted by June 30, 2024, with anticipated approval in the first half of 2025[16]. - The benign stenosis cryoablation system entered confirmatory clinical trials in January 2024, with expected regulatory submission in Q4 2024[17]. - The asthma cryoablation system is currently in confirmatory clinical trials, with expected regulatory submission in the second half of 2025[15]. - The pulmonary hypertension cryoablation system is in preclinical research, with expected regulatory approval by the second half of 2027[13]. - The anti-reflux system is expected to be commercialized in the first half of 2025[11]. - The company has a diverse pipeline of cryoablation systems targeting various medical conditions, indicating a strong focus on innovation and market expansion[11]. Financial Position and Cash Flow - Cash and cash equivalents decreased from RMB 103.5 million as of December 31, 2023, to RMB 69.6 million as of June 30, 2024, a reduction of RMB 33.9 million, or 32.8%[45]. - Net cash used in operating activities for the six months ended June 30, 2024, was RMB 50.4 million, primarily due to significant R&D expenditures[45]. - The current ratio decreased from 4.9 as of December 31, 2023, to 2.5 as of June 30, 2024[49]. - The debt-to-asset ratio increased from 18.5% as of December 31, 2023, to 31.7% as of June 30, 2024[49]. - The company reported a decrease in cash and cash equivalents to RMB 69,563,000 as of June 30, 2024, down from RMB 159,014,000 at the end of the previous year, representing a decline of approximately 56.3%[86]. - The company recorded a net cash outflow from investing activities of RMB 1,419,000 for the first half of 2024, compared to RMB 1,812,000 in the same period of 2023[86]. Shareholder Information - As of June 30, 2024, Mr. Zhu holds 9,721,236 non-listed shares, representing approximately 4.07% of the total issued share capital[64]. - Mr. Lu holds 91,369,084 non-listed shares, representing approximately 38.21% of the total issued share capital[64]. - The total number of issued shares as of June 30, 2024, is 239,110,000 shares[65]. - The company has a significant concentration of ownership, with major shareholders holding over 73% of the total issued share capital[68]. - The ownership structure indicates potential influence on corporate governance and strategic decisions due to concentrated holdings[66]. - The report highlights the importance of shareholder agreements in maintaining control and decision-making processes within the company[66]. Operational Highlights - A distribution agreement was signed in July 2024 with Boston Scientific International Medical Trading (Shanghai) Co., Ltd. for respiratory intervention products in mainland China[7]. - The company has commercialized eight products as of June 30, 2024, with a comprehensive product pipeline focusing on vascular intervention and NOTES[9]. - The company aims to establish itself as a global leader in innovative medical technology within the minimally invasive cryoablation treatment sector[8]. - The company aims to expand its global business selectively while focusing on the commercialization of its pipeline products[33].

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 19,475,000, an increase of 3% from RMB 18,914,000 in the same period of 2023[2] - Gross profit for the same period was RMB 15,281,000, up from RMB 14,638,000, reflecting a gross margin improvement[2] - The net loss for the six months ended June 30, 2024, was RMB (55,953,000), compared to a loss of RMB (47,428,000) in the prior year, representing a 18% increase in losses[2] - Revenue from the sale of medical devices and consumables reached RMB 19,475,000 in the six months ended June 30, 2024, compared to RMB 18,914,000 in the same period of 2023, representing an increase of approximately 2.96%[19] - Other income decreased to RMB 2,122,000 for the six months ended June 30, 2024, down from RMB 3,750,000 in the same period of 2023, reflecting a decline of approximately 43.5%[21] - The group reported a pre-tax loss of RMB 34,330,000 attributed to research and development expenses during the six months ended June 30, 2024[22] - The group recognized a net foreign exchange loss of RMB 3,179,000 for the six months ended June 30, 2023[22] - The company reported a loss attributable to ordinary equity holders of RMB 52,171,000 for the six months ended June 30, 2024, compared to a loss of RMB 43,402,000 for the same period in 2023, representing an increase in loss of approximately 20%[28] - Basic and diluted loss per share for the six months ended June 30, 2024, was RMB (0.22), compared to RMB (0.18) for the same period in 2023, indicating a deterioration in earnings per share[28] - The company has not declared or paid any dividends for the six months ended June 30, 2024, consistent with the previous year[26] Research and Development - Research and development expenses increased to RMB (37,222,000) from RMB (34,330,000), indicating a focus on innovation[2] - The group’s employee benefits expenses, including salaries and wages, amounted to RMB 29,414,000 for the six months ended June 30, 2023[22] - The company has established a product development team consisting of 90 internal R&D staff and 36 clinical operation staff[53] - The company holds 152 patents and has 53 patent applications as of June 30, 2024, to protect its core technologies[54] - The company aims to become a global platform for minimally invasive cryo-interventional medical devices, focusing on rapid clinical development and commercialization of its pipeline products[56] Product Development and Approvals - The company received market approval for its cryo-adhesion treatment system in January 2024, following previous approvals for related products[2][3] - The benign stricture cryoablation system entered the confirmatory clinical trial phase in January 2024[3] - The company submitted registration applications for its malignant stricture cryoablation system and gastroesophageal reflux system[4] - The Cryofocus cryoablation system is designed for hypertension treatment and is expected to receive regulatory approval from the National Medical Products Administration (NMPA) in the second half of 2025[35] - The cardiac cryoablation system received NMPA approval in December 2023, following clinical trials initiated in October 2019[34] - The chronic obstructive pulmonary disease (COPD) cryo-spray treatment system entered confirmatory clinical trials in March 2023, with expected NMPA submission in the second half of 2025 and approval anticipated in the second half of 2026[36] - The asthma cryoablation system is currently in confirmatory clinical trials, with NMPA submission expected in the second half of 2025 and approval anticipated in the second half of 2026[37] - The pulmonary hypertension cryoablation system is in preclinical research, with expected NMPA approval in the second half of 2027[35] - The anti-reflux system is expected to be commercialized in the first half of 2025[34] - The malignant stenosis cryoablation system is designed to treat malignant airway tumors and reduce the frequency of airway re-stenosis[37] - The company has submitted registration applications for several products, indicating a strong pipeline for future growth and market expansion[34] Financial Position - As of June 30, 2024, total non-current assets were valued at RMB 67,944,000, an increase from RMB 62,906,000 at the end of 2023[9] - Current assets decreased to RMB 116,701,000 from RMB 149,915,000, primarily due to a reduction in cash and cash equivalents[9] - Total equity as of June 30, 2024, was RMB 126,028,000, down from RMB 173,460,000 at the end of 2023[12] - Cash and cash equivalents decreased from RMB 1,035 million as of December 31, 2023, to RMB 696 million as of June 30, 2024, a reduction of RMB 339 million or 32.8%[70] - Total debt as of June 30, 2024, was RMB 17,697,000, up from RMB 11,011,000 as of December 31, 2023, representing an increase of approximately 60.5%[73] - The current ratio decreased to 2.5 as of June 30, 2024, from 4.9 as of December 31, 2023, while the debt-to-asset ratio increased to 31.7% from 18.5%[74] Governance and Corporate Structure - The board of directors includes executive directors Mr. Li Kejian, Mr. Zhu Jun, and Mr. Liu Wei, along with non-executive directors Mr. Lv Shiwen and Mr. Zhao Chunsheng, and independent non-executive directors Dr. Gao Dayong, Mr. Liang Xianzhi, Dr. Qin Zheng, and Dr. Hu Henan[93] - The audit committee, consisting of one non-executive director and two independent non-executive directors, has reviewed and confirmed that the interim financial results for the six months ending June 30, 2024, comply with relevant accounting standards and regulations[87] - The board composition reflects a mix of executive and independent directors, which may enhance governance and strategic decision-making[93] - The presence of multiple independent directors may indicate a commitment to transparency and accountability in corporate governance[93] - The emphasis on board diversity may contribute to a broader range of insights and strategies for market expansion[93] Market and Strategic Outlook - The company is focused on biotechnology, suggesting potential developments in health-related products and technologies[93] - The company believes its competitive advantages and product pipeline create high barriers to entry for competitors in the market[31] - The company is likely to discuss future outlook and performance guidance in upcoming communications[93] - The announcement suggests ongoing engagement with stakeholders regarding company performance and strategic direction[93] - The date of the announcement indicates that the company is actively communicating with investors and the market[93]

Financial Performance - In 2023, the company's revenue increased by 50.8% year-on-year, reaching RMB 40,950,000[8] - Gross profit for 2023 was RMB 31,052,000, compared to RMB 19,362,000 in 2022, reflecting a significant improvement[8] - The company reported a net loss of RMB 105,746,000 for 2023, an improvement from a loss of RMB 118,316,000 in 2022[8] - Cash and cash equivalents decreased to RMB 103,402,000 in 2023 from RMB 226,422,000 in 2022[8] - The total equity of the company was RMB 173,460,000 in 2023, down from RMB 259,389,000 in 2022[10] - Revenue increased from RMB 27.1 million for the year ended December 31, 2022, to RMB 41.0 million for the year ended December 31, 2023, representing a growth of 50.8% driven by increased sales of the bladder cryoablation system, lung nodule localization needle, and endoscopic stapler[43] - Gross profit rose from RMB 19.4 million for the year ended December 31, 2022, to RMB 31.1 million for the year ended December 31, 2023, with the overall gross margin increasing from 71.3% to 75.8% due to higher revenue from the lung nodule localization needle and endoscopic stapler[45] Research and Development - R&D expenses increased from RMB 599 million in 2022 to RMB 761 million in 2023, a growth of RMB 162 million or 27.0%[49] - The company has established a product development team consisting of 99 internal R&D staff and 38 clinical operation staff as of December 31, 2023[40] - The company has a comprehensive intellectual property portfolio with 147 patents and 46 patent applications as of December 31, 2023[40] - The company aims to expand its product portfolio based on its cryoablation technology platform and selectively expand its global business[42] - The company has commercialized multiple non-freezing ablation products, including the lung nodule localization needle, endoscopic stapler, and single-port multi-channel laparoscopic surgical access system, with no significant adverse events reported since regulatory approvals[39] Product Development and Approval - The company has developed a comprehensive product portfolio including 14 cryotherapy products and 9 non-cryotherapy products, with 8 products already commercialized[16] - The cardiac cryoablation system is expected to receive approval from the National Medical Products Administration (NMPA) in December 2023, with production quality management review completed in January 2024[19] - The Cryofocus cryoablation system, targeting hypertension, is anticipated to gain NMPA approval in the second half of 2025[20] - The pulmonary hypertension cryoablation system is currently in preclinical research, with expected NMPA approval in the second half of 2027[21] - The COPD cryo-spray treatment system entered confirmatory clinical trials in March 2023, with registration documents expected to be submitted to NMPA in the second half of 2025[22] - The asthma cryoablation system entered confirmatory clinical trials in March 2023, with product registration submission expected in the second half of 2025 and approval anticipated in the second half of 2026[23] - The malignant stenosis cryoablation system is currently in confirmatory clinical trials, with patient recruitment completed; product registration submission is expected in Q2 2024 and approval in the first half of 2025[24] - The benign stenosis cryoablation system entered confirmatory clinical trials in January 2024, with product registration submission expected in Q4 2024 and approval anticipated in the first half of 2026[25] - The lung nodule cryoablation system began feasibility clinical trials in August 2023, with product registration submission expected in the second half of 2026 and approval anticipated in the second half of 2027[27] - The cough cryo-spray treatment system is currently in feasibility clinical trials, with product registration submission expected in the first half of 2025 and approval anticipated in the second half of 2026[28] - The tuberculosis cryo-spray treatment system is also in feasibility clinical trials, with product registration submission expected in the second half of 2025 and approval anticipated in the second half of 2026[29] - The frozen adhesion treatment system received regulatory approval in January 2024, with the system designed for biopsy, stenosis recanalization, and foreign body removal[30] - The bladder cryoablation system was approved by the National Medical Products Administration in June 2022 and commercialized in China in December 2022[31] - The gastric cryoablation system is currently in feasibility clinical trials, with product registration submission expected in the second half of 2025 and approval anticipated in the second half of 2026[32] - The esophageal cryo-spray treatment system is in feasibility clinical trials, with product registration submission expected in the second half of 2025 and approval anticipated in the first half of 2027[33] Management and Governance - The company has expanded its management team with experienced professionals from various medical technology firms, enhancing its strategic decision-making capabilities[80] - The board consists of three executive directors, two non-executive directors, and four independent non-executive directors, ensuring a balance of power and authority[100] - The company has adopted the principles and code provisions of the corporate governance code to regulate its governance practices[97] - The Chief Executive Officer and the Chairman roles are held by different individuals, ensuring a separation of powers[98] - The board includes members with significant experience in financial management and corporate governance, ensuring robust oversight of company operations[81] - The company has established a nomination policy to ensure diversity on the board, considering skills, experience, and knowledge relevant to the company's business[110] - The company has implemented a comprehensive risk management policy to identify, assess, and monitor key risks related to strategic goals[129] - The audit committee is responsible for monitoring significant operational risks and management's handling of these risks[131] Corporate Social Responsibility and ESG - The company identified six highly important ESG issues and ten moderately important issues, focusing on sustainable development management[168] - The company has established an ESG governance structure led by the board of directors, ensuring effective implementation of related policies[163] - The company has implemented strict regulations to combat corruption and fraud, including regular compliance training for senior management and employees[135] - The company has established a whistleblowing policy to report suspicious activities, ensuring confidentiality and protection for whistleblowers[135] - The company has achieved ISO13485:2016 certification for its medical device quality management system, ensuring compliance with regulatory requirements[172] - The company has established a comprehensive quality control program covering the entire product lifecycle, ensuring strict management at all stages from R&D to finished products[178] - The company has implemented measures to ensure sensitive data is handled in compliance with applicable laws and regulations[133] Employee and Gender Diversity - The company employed 392 full-time employees as of December 31, 2023, an increase from 375 in 2022[69] - The board consists of eight male members and one female member, with a commitment to gender diversity and plans to appoint more female directors in the future[126] - The company aims to maintain a minimum of one female director and has achieved 228 female employees, representing 58% of the total workforce[126] - Employee gender ratio as of December 31, 2023, is approximately 42% male to 58% female[127] - The company emphasizes the importance of training and development opportunities for female employees to enhance gender diversity at all levels[126] Supply Chain and Environmental Impact - The company has established a supplier management system with 353 suppliers, including 338 in China and 15 overseas[186] - The company has implemented a green supply chain initiative, encouraging suppliers to use environmentally friendly materials and practices[191] - The company is committed to green operations, focusing on energy conservation and reducing environmental impact[193] - The company achieved a 22% year-on-year reduction in electricity consumption during the reporting period[197] - The company promotes energy-saving concepts among employees and implements measures to maximize energy efficiency[197]